Aiming to characterize CNS progression in patients with breast cancer in the clinical era of trastuzumab, a multicenter cohort of 1012 patients newly diagnosed with metastatic HER2+ breast cancer was followed in a prospective observational study from 2003 to 2006.15 This evidence concerns the gene ERBB2 and breast carcinoma.